The Limited Times

Now you can see non-English news...

The Jeito fund completes its first major sale

2022-11-29T19:33:50.745Z

AstraZeneca is buying Dutch biotech Neogene for $320 million. It's a nice move for Jeito. Nearly three years after its creation, this European venture capital fund specializing in health has completed its first sale to a Big Pharma. The AstraZeneca laboratory acquires the Dutch biotech Neogene Therapeutics, specialized in oncology, for a total amount of up to 320 million dollars. Jeito, who was the first shareholder, accompanied Neogene for two years. He the



It's a nice move for Jeito.

Nearly three years after its creation, this European venture capital fund specializing in health has completed its first sale to a Big Pharma.

The AstraZeneca laboratory acquires the Dutch biotech Neogene Therapeutics, specialized in oncology, for a total amount of up to 320 million dollars.

Jeito, who was the first shareholder, accompanied Neogene for two years.

He then co-led a first round of funding of 110 million dollars.

This operation validates Jeito's strategy, which consists in accelerating the access of patients in therapeutic impasse to new treatments,

summarizes Rafaèle Tordjman, founder of Jeito, which has 534 million euros under management.

We do this by staying as close as possible to the needs of major pharmaceutical companies, while offering as many options as possible to the companies we support.”

To discover

  • Prime Macron 2022: conditions, amount, date of payment... how does it work?

In two years, Jeito has accompanied Neogene from the preclinical phase (in vitro evaluation…

This article is for subscribers only.

You have 68% left to discover.

Cultivating your freedom is cultivating your curiosity.

Keep reading your article for €0.99 for the first month

I ENJOY IT

Already subscribed?

Login

Source: lefigaro

All business articles on 2022-11-29

You may like

Business 2022-12-27T18:56:32.534Z

Trends 24h

Business 2023-01-27T06:51:29.804Z

Latest

© Communities 2019 - Privacy